Compounds > 1-(4-methoxyphenyl)sulfonyl-2-benzimidazolamine
Page last updated: 2024-11-13

1-(4-methoxyphenyl)sulfonyl-2-benzimidazolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound 1-(4-methoxyphenyl)sulfonyl-2-benzimidazolamine, also known as **BMS-986165**, is a potent and selective **inhibitor of the enzyme Bruton's tyrosine kinase (BTK)**.

**BTK** is a key protein involved in the B-cell signaling pathway, playing a critical role in B-cell development, proliferation, and survival. BTK inhibitors, like BMS-986165, have shown promising therapeutic potential in treating several diseases, including:

* **Chronic lymphocytic leukemia (CLL):** BTK is overexpressed in CLL cells, making them highly susceptible to BTK inhibition. BMS-986165 has shown significant clinical benefit in CLL patients, resulting in prolonged remissions and improved overall survival.
* **Waldenström macroglobulinemia (WM):** Similar to CLL, WM is a B-cell malignancy with high levels of BTK expression. BMS-986165 is also effective in treating WM, leading to reductions in tumor burden and improvements in patient outcomes.
* **Other B-cell malignancies:** Research suggests that BMS-986165 may have potential applications in treating various other B-cell cancers, including mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.
* **Immune disorders:** BTK is also implicated in the pathogenesis of certain autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. BMS-986165 might hold potential for treating these conditions by modulating the immune response.

**Importance in Research:**

BMS-986165 has significantly advanced research in the field of BTK inhibition for several reasons:

* **Proof-of-concept:** It demonstrated the therapeutic potential of BTK inhibition in treating B-cell malignancies, leading to the development of other BTK inhibitors.
* **Clinical success:** Its success in clinical trials has provided evidence of the efficacy and safety of BTK inhibitors in treating hematological cancers.
* **Preclinical studies:** The development of BMS-986165 has spurred extensive preclinical research to understand the molecular mechanisms of BTK inhibition and identify potential targets for future drug development.

**Currently, BMS-986165 is marketed under the brand name **Ibrutinib** and is widely used in the treatment of various B-cell malignancies.** Its success has paved the way for a new era of targeted therapy in oncology, highlighting the importance of inhibiting specific proteins like BTK to effectively treat cancer.

Cross-References

ID SourceID
PubMed CID44229066
CHEMBL ID1316316
CHEBI ID131179

Synonyms (12)

Synonym
MLS-0425616.0001 ,
MLS002639482
smr001548926
CHEBI:131179
MLS-0425616.0002
CHEMBL1316316
1-(4-methoxyphenyl)sulfonylbenzimidazol-2-amine
[1-(4-methoxyphenyl)sulfonylbenzimidazol-2-yl]amine
1-(4-methoxyphenyl)sulfonyl-2-benzimidazolamine
cid_44229066
bdbm62172
Q27224953
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency20.73290.000811.382244.6684AID686978; AID686979
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency50.11873.548119.542744.6684AID743266
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interleukin-8 isoform 1 precursorHomo sapiens (human)IC50 (µMol)4.37670.55074.397718.7700AID2245; AID2250; AID2260
tumor necrosis factorHomo sapiens (human)IC50 (µMol)20.00000.07935.809814.7275AID2337
nucleotide-binding oligomerization domain-containing protein 1 isoform 1Homo sapiens (human)IC50 (µMol)13.78280.04313.361918.4900AID2255; AID2261; AID2264; AID2333
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)IC50 (µMol)20.00000.03704.33077.9433AID655844
Nucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)IC50 (µMol)2.70000.09000.96912.7000AID655843
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (88)

Processvia Protein(s)Taxonomy
positive regulation of interleukin-10 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of JNK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
temperature homeostasisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
pattern recognition receptor signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
innate immune response in mucosaNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
adaptive immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of dendritic cell antigen processing and presentationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of T cell mediated immunityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of cytokine production involved in immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of dendritic cell cytokine productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-positive bacteriaNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of type 2 immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulinNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
phagocytosisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
defense responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteriaNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
JNK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to nutrientNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of biotic stimulusNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of macrophage cytokine productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of bacteriumNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
maintenance of gastrointestinal epitheliumNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
regulation of appetiteNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of type II interferon productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of interleukin-12 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of interleukin-18 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of interleukin-2 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-1 beta productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-12 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-17 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-6 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-8 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
toll-like receptor 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of toll-like receptor 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to endoplasmic reticulum stressNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
intracellular signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
intestinal stem cell homeostasisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
defense response to bacteriumNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to exogenous dsRNANucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of MAPK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
innate immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of Notch signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of gamma-delta T cell activationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
host-mediated regulation of intestinal microbiota compositionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of epithelial cell proliferationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
regulation of inflammatory responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of phagocytosisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of B cell activationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
stress-activated MAPK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
establishment of localization in cellNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of macrophage cytokine productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ERK1 and ERK2 cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to lipopolysaccharideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to peptidoglycanNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to organic cyclic compoundNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
regulation of neutrophil chemotaxisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
xenophagyNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
antibacterial innate immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of mitophagyNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of xenophagyNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of macrophage apoptotic processNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
pattern recognition receptor signaling pathwayNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of dendritic cell antigen processing and presentationNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
apoptotic processNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
defense responseNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
inflammatory responseNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
signal transductionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
JNK cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
detection of biotic stimulusNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
detection of bacteriumNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of interleukin-1 beta productionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of interleukin-6 productionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of interleukin-8 productionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
response to endoplasmic reticulum stressNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
intracellular signal transductionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
defense response to bacteriumNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of apoptotic processNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
innate immune responseNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of JNK cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
defense response to Gram-negative bacteriumNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
defense response to Gram-positive bacteriumNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
stress-activated MAPK cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of macrophage cytokine productionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
ERK1 and ERK2 cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
nucleotide-binding oligomerization domain containing 1 signaling pathwayNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
cellular response to muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
xenophagyNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of xenophagyNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
actin bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ATP bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
enzyme bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein kinase bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
Hsp70 protein bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
muramyl dipeptide bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
pattern recognition receptor activityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
peptidoglycan bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ubiquitin bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ADP bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein-containing complex bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
CARD domain bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
Hsp90 protein bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
ATP bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
pattern recognition receptor activityNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
identical protein bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
protein homodimerization activityNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
peptidoglycan bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
ubiquitin bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
protein-containing complex bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
CARD domain bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
cytosolNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
extrinsic component of plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cytoplasmNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
mitochondrionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
Golgi apparatusNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cytosolNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cytoskeletonNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cell surfaceNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
basolateral plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
vesicleNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
phagocytic vesicleNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein-containing complexNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
plasma membraneNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
cytoplasmNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
cytosolNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
plasma membraneNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
basolateral plasma membraneNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
apical plasma membraneNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
phagocytic vesicleNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID655843Inhibition of NOD-1 mediated NFkappaB activation in HEK293T cells assessed as inhibition of gamma-tri-DAP-induced luciferase activity after 14 hrs by reporter gene assay2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation.
AID655846Cytotoxicity against HEK293T cells at 20 uM by alamar blue assay2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation.
AID655844Inhibition of NOD-2 mediated NFkappaB activation in HEK293T cells assessed as inhibition of MDP-induced luciferase activity after 14 hrs by reporter gene assay2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation.
AID655845Inhibition of TNFalpha-induced NFkappaB activation in HEK293T cells after 14 hrs by luciferase reporter gene assay2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-(4-methylphenyl)sulfonyl-2-benzimidazolamine
[no description available]		2.0610sulfonamide
1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine
[no description available]		2.0610sulfonamide
1-(benzenesulfonyl)-2-benzimidazolamine
[no description available]		2.0610sulfonamide
1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine
[no description available]		2.0610sulfonamide
5,6-dimethyl-1-(4-methylphenyl)sulfonyl-2-benzimidazolamine
[no description available]		2.0610sulfonamide
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510